? ?Dexmedetomidine Hydrochloride (CAS 145108-58-3) | Pharmaceutical-Grade Sedative Agent? ?

?? ?Product Overview?

?Dexmedetomidine Hydrochloride? (CAS 145108-58-3) is a highly selective ?α2-adrenoceptor agonist? with potent sedative and analgesic properties. This white to off-white crystalline powder (≥99% purity, HPLC) is widely used in critical care and perioperative settings to reduce anxiety and pain while maintaining patient responsiveness. Its molecular formula is ?C??H??ClN??, with a molecular weight of ?236.74?.

?Primary Functions?:

• Induces sedation without respiratory depression.

• Reduces opioid requirements during surgery.

• Enhances hemodynamic stability in ICU patients.

?Target Industries?: Pharmaceuticals, hospital care, anesthesia management.

? ?Key Advantages?

?? ?Applications?

• ?Intensive Care?

  : Sedation for mechanically ventilated patients.

• ?Surgical Anesthesia?

  : Adjunct to general or regional anesthesia.

• ?Diagnostic Procedures?

  : Non-invasive sedation (e.g., MRI, CT scans).

?? ?Quality Assurance?

• ?Testing Protocols?

  : NMR, HPLC, mass spectrometry, and residual solvent analysis.

• ?Stability?

  : Long-term storage at 

  ?2-8°C?

   in sealed containers.

• ?Regulatory Alignment?

  : Complies with ICH Q7 and GMP guidelines.

?? ?Market Insights?

The global sedation drugs market is projected to reach ?$6.2 billion by 2030?, driven by increasing surgical volumes and ICU admissions. Dexmedetomidine demand is rising at ?7.1% CAGR?, particularly in Asia-Pacific regions due to expanding healthcare infrastructure.